66515-29-5
基本信息
2-Methyl-O- phosphonoserine
Serine, 2-methyl-O-phosphono-
(RS)-α-Methylserine-O-phosphate
(R,S)-a-Methylserine-O-phosphate
(RS)-ALPHA-METHYLSERINE-O-PHOSPHATE
物理化学性质
| 沸点 | 454.0±55.0 °C(Predicted) |
| 密度 | 1.681±0.06 g/cm3(Predicted) |
| 储存条件 | Store at RT |
| 溶解度 | 在水中的溶解度为性3mg/mL，澄清（加热） |
| 酸度系数(pKa) | 1.66±0.10(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| 水溶解性 | 溶于水至100mM |
安全数据
| 危险性符号(GHS) |  GHS06 |
| 警示词 | 危险 |
| 危险性描述 | H301 |
| 防范说明 | P301+P310 |
| 危险品标志 | T |
| 危险类别码 | 25 |
| 安全说明 | 45 |
| 危险品运输编号 | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
常见问题列表
K D : 51 μM (L-AP4-sensitive presynaptic mGluR).
In the presence of 200 μM MSOP, a rightward parallel shift of the dose-response curve to L-AP4 is observed, with an apparent K D calculated as 51±6 μM (n=3). MSOP is shown to be selective for the L-APC sensitive presynaptic mGluR, the apparent K D for the interaction of MSOP with the (1S, 3S)-ACPD sensitive receptor calculated as greater than 700 μM (n=3).
It is found that TBOA-induced antinociceptive effects are significantly blocked by intrathecal co-administration of MSOP (second phase of formalin model: F 3,16 =30.96, P<0.001; CFA model: F 3,16 =30.77, P<0.001). As expected, intrathecal TBOA (10 μg) reduces the number of formalin-induced flinches and shakes by 47% of the value in the saline-treated group in the second phase (P<0.001) and blocked the CFA-induced decrease in ipsilateral paw withdrawal latency by 60% of the value in the saline-treated group (P=0.01). The number of formalin-induced flinches in the second phase in the group treated with MSOP and TBOA is increased by 56% (P=0.04) of the value in the TBOA-treated group. CFA-induced paw withdrawal latency in the group treated with MSOP and TBOA is decreased by 86% (P=0.03) of the value in the TBOA-treated group.